018680 — Seoul Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,232	40,463	50,057	52,459	53,580
Cost of Revenue
Gross Profit	35,228	25,483	32,146	31,588	32,929
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	41,919	46,375	50,495	51,246	52,052
Operating Profit	10,313	-5,912	-438	1,213	1,528
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1,174	-9,592	-1,120	4,044	1,760
Provision for Income Taxes
Net Income After Taxes	-1,342	-9,689	855	3,517	1,699
Net Income Before Extraordinary Items
Net Income	-1,342	-9,689	855	3,517	1,699
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,342	-9,689	855	3,517	1,699
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-479	-1,122	253	302	144
Dividends per Share